Day: February 7, 2020

BOISE, Idaho, Feb. 07, 2020 (GLOBE NEWSWIRE) — Micron Technology, Inc. (Nasdaq: MU), announced today that it will hold its fiscal second quarter earnings conference call on Wednesday, March 25, 2020 at 2:30 p.m. Mountain time. A live webcast of the call will be available via Micron’s Investor Relations website at investors.micron.com. A webcast replay will be available for approximately one year after the call.As a reminder, Micron Technology Chief Business Officer Sumit Sadana and Chief Financial Officer David Zinsner will participate in a fireside chat at the Goldman Sachs Technology and Internet Conference 2020 in San Francisco, California. The event will now be webcast live at 10:20 a.m. Pacific time on Tuesday, Feb. 11.Live webcasts and subsequent replays of presentations can be accessed from Micron’s Investor Relations...

CALGARY, Alberta, Feb. 07, 2020 (GLOBE NEWSWIRE) — Marksmen Energy Inc. (“Marksmen” or the “Company”) (TSXV: MAH) (OTCQB: MKSEF) announces that it plans to complete a non-brokered private placement of up to 4,500,000 units (the “Units”) of Marksmen at a price of $0.05 per Unit for aggregate gross proceeds of up to a maximum of $225,000 (the “Offering”). There is no minimum Offering. The Units will be comprised of one (1) common share (“Common Share”) and one (1) share purchase warrant (“Warrant”) of Marksmen. Each whole Warrant entitles the holder thereof to purchase one Common Share for $0.10 expiring two (2) years from the date of the closing of the Offering.Marksmen may pay a cash commission or finder’s fee to qualified non-related parties...

NEW YORK, Feb. 07, 2020 (GLOBE NEWSWIRE) — WW International, Inc. (NASDAQ: WW) will release its results for the fourth quarter and full year 2019 after market close on Tuesday, February 25, 2020.WW will host a conference call at 5:00 p.m. ET the same day. During the conference call, Mindy Grossman, President and Chief Executive Officer, and Nicholas Hotchkin, Chief Financial Officer, Operating Officer, North America & President, Emerging Markets, will discuss the fourth quarter and full year 2019 results and answer questions from the investment community.The live webcast of the conference call will be available on the Company’s corporate website, corporate.ww.com, in the Investors section under Presentations and Events.  Supplemental investor materials will also be available in the same location prior to the start...

PHILADELPHIA, Pa. and OXFORD, United Kingdom, Feb. 07, 2020 (GLOBE NEWSWIRE) — Adaptimmune Therapeutics plc (“Adaptimmune”) (Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, today announced that the underwriters of its previously announced public offering of 21,000,000 American Depositary Shares (“ADSs”), which initially closed on January 24, 2020, have exercised in full their option to purchase an additional 3,150,000 of its ADSs at a price to the public of $4.00 per ADS, raising additional net proceeds of approximately $11.7 million, after deducting underwriting discounts and commissions and estimated offering expenses. The option exercise closed on February 7, 2020.  After giving effect to the option exercise, Adaptimmune sold a total of 24,150,000 ADSs in connection with the offering,...

MAROUSSI, ATHENS, Greece, Feb. 07, 2020 (GLOBE NEWSWIRE) — EuroDry Ltd. (NASDAQ: EDRY) (the “Company”), an owner and operator of drybulk vessels and provider of seaborne transportation for drybulk cargoes, announced that it will release its financial results for the fourth quarter ended December 31, 2019 on Wednesday, February 12, 2020 after the market closes in New York.On Thursday, February 13, 2020 at 10:00 a.m. Eastern Time, the Company’s management will host a conference call and webcast to discuss the results.Conference Call details:Participants should dial into the call 10 minutes before the scheduled time using the following numbers: 1 (877) 553-9962 (US Toll Free Dial In), 0(808) 238- 0669 (UK Toll Free Dial In) or +44 (0) 2071 928592 (Standard International Dial In). Please quote “EuroDry”...

HIGH POINT, N.C., Feb. 07, 2020 (GLOBE NEWSWIRE) — vTv Therapeutics Inc. (Nasdaq: VTVT) today announced that it will release the topline results from Part 2 of the Phase 2 Simplici-T1 trial assessing TTP399 as an oral adjunctive therapy to insulin in adults with type 1 diabetes (T1D) on Monday, February 10th at 7:00am ET.  vTv Therapeutics’ leadership team will then host an investor conference call that day at 8:30am ET.In June 2019, the company announced positive results from Part 1 of the Phase 2 study that showed a statistically significant reduction in HbA1c without increases in ketoacidosis or hypoglycemia. In Part 1, TTP399 was well tolerated with similar incidences of treatment-emergent adverse events overall and by system organ class. Part 1 had no serious adverse event reported, and no report of diabetic...

SÃO PAULO, Brazil, Feb. 07, 2020 (GLOBE NEWSWIRE) — Arco Platform Limited, or Arco (Nasdaq: ARCE), today announced that it will report fourth quarter and fiscal year 2019 financial results for the period ended December 31, 2019, following the close of the market on Monday, March 16, 2020. The Company will host a corresponding conference call and webcast at 4:30 p.m. Eastern time on that day.Investors may listen to the conference call (ID: 7458624) by dialing (866) 679-4032 or +1 (409) 217-8315 at 4:30 p.m. Eastern Time on March 16, 2020. An audio replay of the call will be available through March 30, 2020 by dialing (855) 859-2056 or +1 (404) 537-3406 and entering access code 7458624. A live and archived webcast of the call will be available on the Investor Relations section of the Company’s website at https://arcoeducacao.gcs-web.com/.About...

VANCOUVER, British Columbia, Feb. 07, 2020 (GLOBE NEWSWIRE) — Fancamp Exploration Ltd. (“Fancamp” or the “Company”) (TSXV: FNC) is pleased to announce that the Company has completed the closing of a second tranche in connection with its previously announced (Fancamp News Release dated December 27, 2019) non-brokered private placement financing of up to 5,791,000 flow-through shares of the Company for gross proceeds of up to Cdn$450,000.At closing of the second tranche of the private placement, the Company issued 1,200,000 flow-through shares for gross proceeds of Cdn$90,000 (the “Second Tranche”). Each flow-through share issued in connection with the Second Tranche is subject to a four-month hold period under applicable securities laws in Canada, which hold period shall end on June 8, 2020.The...

MENLO PARK, Calif., Feb. 07, 2020 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (Nasdaq:PACB), a leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, today announced that Michael Phillips has decided to retire from his role as the company’s Senior Vice President of Research and Development as of April 1, 2020.Mr. Phillips has directed the development of PacBio’s technology since joining the company in 2005. During his tenure, he oversaw the development of the company’s first system, the PacBio RS, which was launched in 2011, and each of the company’s follow-on systems, including the PacBio RS II in 2013, the Sequel System in 2015, and most recently the Sequel II System in 2019.“It has truly been an honor to lead Research and Development at Pacific Biosciences...

SOUTH SAN FRANCISCO, Calif., Feb. 07, 2020 (GLOBE NEWSWIRE) — CytomX Therapeutics, Inc. (NASDAQ:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody® therapeutic technology platform, today announced that on February 3, 2020, the Company granted its recently appointed senior vice president and chief medical officer, Alison L. Hannah, M.D., an option to purchase 250,000 shares of the Company’s common stock at an exercise price per share equal to $7.71, which was the closing trading price on February 3, 2020, the date of the grant. The Company also granted Dr. Hannah a performance option to purchase 50,000 shares of the Company’s common stock at an exercise price per share equal to $7.71. The performance option vests...